News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
454,315 Results
Type
Article (24855)
Company Profile (90)
Press Release (429370)
Section
Business (130148)
Career Advice (1420)
Deals (24259)
Drug Delivery (82)
Drug Development (66193)
Employer Resources (58)
FDA (11373)
Job Trends (9968)
News (232084)
Policy (20258)
Tag
Academia (1822)
Alliances (28692)
Alzheimer's disease (1038)
Approvals (11354)
Artificial intelligence (108)
Bankruptcy (188)
Best Places to Work (8313)
Breast cancer (175)
Cancer (1303)
Cardiovascular disease (95)
Career advice (1128)
Cell therapy (229)
Clinical research (53897)
Collaboration (410)
Compensation (204)
COVID-19 (1917)
Cystic fibrosis (81)
Data (1301)
Diabetes (190)
Diagnostics (4388)
Earnings (63884)
Events (68803)
Executive appointments (301)
FDA (11970)
Funding (363)
Gene therapy (155)
GLP-1 (686)
Government (2924)
Healthcare (13272)
Infectious disease (1998)
Inflammatory bowel disease (103)
Interviews (258)
IPO (13004)
Job creations (2062)
Job search strategy (977)
Layoffs (294)
Legal (3999)
Lung cancer (191)
Lymphoma (95)
Manufacturing (181)
Medical device (8782)
Medtech (8783)
Mergers & acquisitions (11508)
Metabolic disorders (507)
Neuroscience (1327)
NextGen Class of 2024 (4094)
Non-profit (3751)
Northern California (1417)
Obesity (290)
Opinion (131)
Parkinson's disease (90)
Patents (82)
People (30457)
Phase I (18258)
Phase II (23112)
Phase III (17409)
Pipeline (495)
Postmarket research (1854)
Preclinical (6159)
Radiopharmaceuticals (209)
Rare diseases (229)
Real estate (3117)
Regulatory (14499)
Research institute (1716)
Resumes & cover letters (267)
Southern California (1213)
Startups (2079)
United States (12019)
Vaccines (458)
Weight loss (226)
Date
Last 7 days (135)
Last 30 days (1393)
Last 365 days (28027)
2025 (73)
2024 (28552)
2023 (30850)
2022 (39748)
2021 (41673)
2020 (38644)
2019 (31946)
2018 (24419)
2017 (22939)
2016 (20545)
2015 (24092)
2014 (17161)
2013 (13416)
2012 (14065)
2011 (14685)
2010 (13546)
Location
Africa (512)
Arizona (90)
Asia (27976)
Australia (4745)
California (3116)
Canada (1204)
China (290)
Colorado (116)
Connecticut (157)
Europe (63348)
Florida (404)
Georgia (109)
Illinois (294)
Indiana (176)
Japan (82)
Maryland (490)
Massachusetts (2425)
Michigan (136)
Minnesota (209)
New Jersey (928)
New York (873)
North Carolina (595)
Northern California (1417)
Ohio (104)
Pennsylvania (697)
South America (753)
Southern California (1213)
Texas (433)
Utah (82)
Washington State (303)
454,315 Results for "alpha 1 foundation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CND Life Sciences Receives Grant from The Michael J. Fox Foundation to Study Quantification of Cutaneous Phosphorylated Alpha-Synuclein (P-SYN) in People with Parkinson’s Disease
November 20, 2024
·
4 min read
Press Releases
FDA Approves AChEI ALPHA-1062 for Alzheimer’s Disease Treatment
On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.
August 2, 2024
·
2 min read
Press Releases
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
December 11, 2024
·
10 min read
Press Releases
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
November 21, 2024
·
6 min read
Press Releases
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
December 11, 2024
·
4 min read
Drug Development
Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma
Alpha-9 Oncology announced that the first participant has been dosed in the Phase 1 study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor for the imaging of locally advanced or metastatic melanoma.
May 2, 2024
·
2 min read
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
Alpha Tau Medical Ltd. announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada.
May 13, 2024
·
6 min read
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV).
November 15, 2023
·
6 min read
Alpha Tau to Participate in May 2024 Investor Conferences
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that CFO Raphi Levy will present at the following investor conferences in May 2024.
May 1, 2024
·
1 min read
Press Releases
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium
December 6, 2024
·
1 min read
1 of 45,432
Next
